乳腺癌耐药蛋白的研究现状
被引量:1
Present status of research on drug-tolerant proteins of breast cancer
摘要
乳腺癌耐药蛋白是一种新发现的耐药蛋白,其介导的多药耐药与P-糖蛋白(P-gp)不同,在肿瘤组织中的表达情况差异较大。笔者就乳腺癌耐药蛋白的结构特性及其介导的多药耐药及在肿瘤中的表达情况等研究现状作一综述。
出处
《中国普通外科杂志》
CAS
CSCD
2005年第9期702-704,共3页
China Journal of General Surgery
参考文献19
-
1Doyle LA,Yang W,Abruzzo LA, et al. A muhidrug transporter from human MCF-7 breast cancer cells [ J ].Proc Natl Sci USA, 1998, 95(26) :15665 -15670.
-
2Allikmets R,Schriml LM,Hutchinson A,et al. A human placenta-specific ATP-binding cassette gene ( ABCP )on chromosome 4q22 that is involved in muhidrug resistance [ J ]. Cance Res, 1998, 58 ( 23 ) : 5337 -5339.
-
3Miyake K, Mickley L, Litman T, et al. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells : demonstration of homology to ABC transport genes [ J ].Cancer Res, 1999, 59 ( 1 ) : 8 -13.
-
4Brangi M,Litman T,Hudson E,et al.The muhidrug-resistant phenotype associated with overaxpression of the ABC half-transporter,MXR(ABCG2 ) [ J ]. Annal Oncol,2000.11 (Supple 2) :13.
-
5Yang CH, Chert YC, Kao ML, et al. Novobiocin sensitizes BCRP/MXR/ABCP overexpressing topotecan-resistant human breast carcinoma cells to topotecan and mitoxantrone [ J ].Anticancer Res, 2003, 23 (3B) :2519-2523.
-
6Faneyte IF, Kristel PM, Maliepaard M, et al. Expression of the breast cancer resistance protein in breastcancer [ J ]. Clin Cancer Res,2002.8(4) :1068 - 1074.
-
7Sugimoto Y, Tsukahara S, Imai Y, et al. Reverasl of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists[ J ] Mol Cancer Ther, 2003, 2(1) :105 - 112.
-
8Honjo Y, Hrycyna CA,Yan QW, et al. Acquired mutations in the MXR/BCRP/ ABCP gene alter substrate specificity in MXR/BCRP/ABCP- overexpressing cells(j).Cancer Res,2001,61 ( 18 ) : 663 -6639.
-
9Volk EL, Farley KM,Wu Y, et al.Overexpression of wild - type breast resistance protein mediates methotrexate resistance [ J ] . CancerRes, 2002, 62 ( 17 ) : 5035 -5040.
-
10Rajendra R, Gounder MK, SaleemA, et al.Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9 - aminocamptothecin and 9 - nitro-camptothecin[J]. Cancer Res,2003, 63 (12): 3228-3233.
同被引文献14
-
1Kuo MT. Roles of multidrug resistance genes in breast cancer chemoresistance [ J ] . Adv Exp Med Biol, 2007 , 608 ( 1 ) : 23 -30.
-
2Breast cancer. Advances in diagnosis and treatment [ J ]. Mayo Clin Health Lett, 2009, Suppl : 1 - 8.
-
3Tsang CM, Lau EP, Di K, et al. Berberine inhibits Rho GTPases and cell migration at low doses but induces G2 arrest and apoptosis at high doses in human cancer cells [ J ]. Int J Mol Med,2009,24(1) :131 -138.
-
4Zhang S, Schafer-Hales K, Khuri FR, et al. The tumor suppressor LKB 1 regulates lung cancer cell polarity by mediating cdc42 recruitment and activity [ J ]. Cancer Res,2008, 68(3) :740 -748.
-
5Jiang P, Enomoto A, Takahashi M. Cell biology of the movement of breast cancer cells : intracellular signalling and the actin cytoskeleton[ J]. Cancer Lett,2009,284(2) :122 - 130.
-
6Li X, Li JP, Yuan HY, et al. Recent advances in P-glycoprotein- mediated multidrug resistance reversal mechanisms [J]. Methods Find Exp Clin Pharmacol,2007,29 (9) : 607 -617.
-
7Li X, Sun B, Zhu C J, et al. Reversal of p-glycoproteinmediated muhidrug resistance by macrocyclic bisbibenzyl derivatives in adriamycin-resistant human myelogenous leukemia (K562/A02) cells[J]. Toxicol In Vitro,2009,23(1) : 29 -36.
-
8Boumendjel A, Baubichon-Cortay H, Trompier D, et al. Anticancer muhidrug resistance mediated by MRP 1 : recent advances in the discovery of reversal agents [ J ]. Med Res Rev, 2005,25(4) :453 -472.
-
9Ishikawa T, Kuo MT, Furuta K, et al. The human muhidrug resistance-associated protein (MRP) gene family: from biological function to drug molecular design [ J ] . Clin Chem Lab Med,2000,38(9) :893 -897.
-
10Scheffer GL, Kool M, Heijn M, et al. Specific detection of multidrug resistance proteins MRP1 , MRP2, MRP3 , MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies[J]. Cancer Res,2000,60(18) :5269-5277.
二级引证文献6
-
1江隆昌,张勇,屈新才.细胞分裂周期蛋白42高表达在雌激素诱导的乳腺癌细胞耐药性增强过程中的作用[J].中华肿瘤杂志,2011,33(7):489-493. 被引量:2
-
2吴晓静,庞雁,庹培昱,刘江,牛瑞芳,常克力.导向逆转剂Ab-IL2体外偶联以及协同抑瘤作用的研究[J].中国肿瘤临床,2011,38(20):1251-1253.
-
3周栋,徐亮,李建国.磷脂酰肌醇蛋白聚糖-3在乳腺癌组织中的表达及其意义[J].中国普通外科杂志,2011,20(11):1216-1220. 被引量:2
-
4范立侨,李勇,赵群,檀碧波,孙川,李兆星,王冬,刘羽.人胃癌细胞原位移植裸鼠原发灶与肝转移灶体外化疗药敏性差异[J].中国普通外科杂志,2013,22(10):1280-1284. 被引量:4
-
5李君,张煜,陈厚文,熊丽霞.Cdc42在乳腺癌中的作用[J].中国细胞生物学学报,2018,40(7):1223-1230. 被引量:4
-
6武诺帆,罗苗苗,陈尧禹,汪香荣,陈雯雯,王鹏,陈俊.Cdc42表达载体构建及协同药物对细胞迁移的影响[J].生物医学,2021,11(3):176-185.
-
1付巧梅,陈宏伟,吴鹏西.甲状腺微小癌的超声结构特性及其诊断价值[J].海南医学,2014,25(3):358-360. 被引量:3
-
2段勇,杨桂玲,李剑.血管内皮细胞生长因子及其受体与白血病[J].江西医学检验,2004,22(4):352-353.
-
3高洪波,巩平,李娜.组织多肽特异性抗原(TPS)临床研究进展[J].现代肿瘤医学,2010,18(3):602-605. 被引量:12
-
4李育超,周克元.非环式维甲酸类化学预防肝癌的研究进展[J].国际检验医学杂志,2006,27(5):413-415. 被引量:1
-
5张亚江,彭诗东.COX-2和CRIPTO-1在喉癌靶向治疗中的应用与展望[J].疾病监测与控制,2012,6(2):80-81. 被引量:1
-
6王健瑜,刘利,谢庭菊.雌激素受体亚型及其与肿瘤关系的研究进展[J].西南国防医药,2009,19(12):1303-1304. 被引量:2
-
7吕朋,李八方,夏兰.壳聚糖在医药保健中的应用[J].中国海洋药物,2001,20(5):30-34. 被引量:26
-
8宋媛,梁琳琅.脂联素及其受体与结肠直肠肿瘤关系的研究进展[J].中国医学工程,2011,19(5):177-178.
-
9卫静,邹利光,廖翠薇,可金星.大鼠肝细胞癌微血管超微结构的透射电镜观察[J].电子显微学报,2004,23(4):322-322.
-
10陈平,刘美玉,钱纬,李维波,魏万里,张学惠.乳腺癌癌细胞超微结构形态参数的逐步回归分析[J].数理医药学杂志,2000,13(1):1-3. 被引量:1